Montana hearing on HB 783 examines insurer costs, medical access for GLP‑1 weight‑loss drugs

Representative Scott Rosenzweig, sponsor of House Bill 783, opened the committee hearing by urging lawmakers to require insurers to pay for clinically prescribed glucagon‑like peptide‑1 (GLP‑1) medications for patients at high risk of developing type 2 diabetes.

Rosenzweig said the bill would require coverage before a patient becomes diabetic, targeting ‘‘class 3 obesity’’ — a body mass index of 40 or greater — and serious weight‑related complications. ‘‘Insurers should pay for medically necessary weight loss drugs before a patient becomes diabetic instead of requiring them to become diabetic in order to qualify,’’ Rosenzweig said.

Nut graf: The committee heard competing views on clinical benefits and budgetary impact. Physicians’ groups and some legislators argued the drugs can prevent costly chronic disease and improve quality of life for a narrowly defined population; private insurers and small plans warned the mandate would materially raise premiums and produce large state defrayal costs under Montana’s reimbursement process.

Physicians and advocacy groups told the committee doctors are best positioned to judge medical necessity. Jean Branscum, CEO of the Montana Medical Association, said ‘‘these decisions…